Intraoperative findings were: no infiltration of the left renal capsule and excess fat cyst; no enlarged lymph node observed near the kidney; a 30 25 mm white gray tumor in the left renal pelvis; and a bean-sized malignancy embolus in the vein of the left kidney. individual with main MFH of the renal pelvis who has survived a 78-month tumor-bearing follow-up. == Case statement == A 71-year-old woman was admitted Vaniprevir because of recurrent macroscopic hematuria of more than 1 year and the magnetic resonance imaging (MRI) obtaining of a space-occupying lesion in the right renal pelvis that had been there for more than 1 month. A year earlier, she experienced undergone a B-type ultrasound, a computed tomography scan (CT), and MRI of the urinary system because of macroscopic hematuria, but no significant abnormality had been found. After discontinuation of anticoagulants for coronary heart disease, the hematuria subsided. In 2011, macroscopic hematuria was recurrent and self-limited. One month prior to presenting, macroscopic hematuria appeared again, when MRI suggested a space-occupying lesion in the right renal pelvis (Physique 1A). == Physique 1. == (A) Preoperative magnetic resonance image; (B) pathologic section; (C) computed tomography (CT) re-examination at 9 months suggesting metastasis near the abdominal aorta; (D) CT re-examination at 18 months showing no enlarged lymph node near the abdominal aorta. Physical examination indicated no excess weight loss, stable Vaniprevir vital indicators, no palpable mass in the stomach, and no percussive pain over the kidneys bilaterally. A B-type ultrasound suggested left hydronephrosis and space occupation. On December 20, 2006, radical nephrectomy, renal vein malignancy embolus resection, and peripheral lymph node clearance were performed under general anesthesia. Intraoperative findings were: no infiltration of the left renal capsule and excess fat cyst; no enlarged lymph node observed near the kidney; a 30 25 mm white gray tumor in the left renal pelvis; and a bean-sized cancer embolus in the vein of the left kidney. Postoperative pathology reported MFH of the left kidney associated with renal-vein cancer embolus (Figure 1B). Immunohistochemistry showed Vaniprevir vimentin (+) and cluster of differentiation (CD) 68 (+) (Figure 2). (All antibodies were purchased from Maixin Biotech [Fuzhou, Peoples Republic of China], and used at dilution 1:100). == Figure 2. == Immunostaining for cluster of differentiation 68, S-100, and vimentin. Note: Scale bar 20 m. A bone ECT scan and plain thoraco-abdominal CT scan during a 9-month postoperative follow-up period showed a metastatic focus adjacent to the abdominal aorta (Figure 1C), whose CT value was similar to that of the primary tumor. The patient was re-admitted for radiotherapy for 3 months. CT scans at 12 and 18 months following the operation showed that the metastatic focus near the abdominal aorta had disappeared (Figure 1D). The patient refused any further treatment, and at the time of writing, 78 months after her first operation, she remains alive. == Discussion == Renal MFH is a malignant tumor originating from mesenchymal tissue, the pathogenesis of which is unclear. Some researchers believe it is related to scar repair, radiation, chemicals, and/or viral infection.16There have been few Vaniprevir cases reported in the literature since Anderson et al reported the first case in 1977. Clinically, MFH of the renal pelvis is similar to carcinoma of the renal pelvis, the diagnosis of which mainly depends on postoperative histology. As the histological presentation of MFH is complex in composition and variable in morphology, it is difficult to use routine pathology to confirm the diagnosis. Immunohistochemistry and/or electron microscopy are needed to confirm the diagnosis. CD68 has become a routine Rabbit Polyclonal to GPR108 and specific cytohistological marker of MFH5to replace the former marker alpha-1 antichymotrypsin, which is stained positive for malignant histiocytes by immunohistochemistry under microscopy. Nemes and Thomazy17emphasized that being positive for Factor VIIIa represents the differentiation level of fibrous histiocytes, and that in soft-tissue tumors with similar pathological morphological profiles, testing positive for Factor VIIIa is the cue for the diagnosis of MFH. Direct invasion is the main characteristic of MFH growth and dissemination, followed by blood and lymph node metastasis, which is usually found at the time of diagnosis. 16MFH is highly malignant, with a high rate of local recurrence and distal metastasis. Fukunaga18reported that MFH originating from the renal pelvis is highly malignant, and most patients die within 12 months of surgical intervention. It is generally accepted that early diagnosis, surgical resection, and accessory radiotherapy/chemotherapy are the main.